Brainstorm Cell Therapeutics (NASDAQ: BCLI) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

12.7% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Esperion Therapeutics shares are held by institutional investors. 23.7% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 32.5% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Brainstorm Cell Therapeutics and Esperion Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brainstorm Cell Therapeutics N/A -56.24% -51.18%
Esperion Therapeutics N/A -62.82% -57.32%

Analyst Ratings

This is a summary of current ratings and recommmendations for Brainstorm Cell Therapeutics and Esperion Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainstorm Cell Therapeutics 0 0 1 0 3.00
Esperion Therapeutics 0 5 8 0 2.62

Brainstorm Cell Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 116.87%. Esperion Therapeutics has a consensus target price of $55.21, suggesting a potential upside of 8.91%. Given Brainstorm Cell Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Esperion Therapeutics.

Valuation & Earnings

This table compares Brainstorm Cell Therapeutics and Esperion Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Brainstorm Cell Therapeutics N/A N/A -$5.06 million ($0.28) -14.82
Esperion Therapeutics N/A N/A -$131.29 million ($5.78) -8.77

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Brainstorm Cell Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500.

Summary

Brainstorm Cell Therapeutics beats Esperion Therapeutics on 6 of the 10 factors compared between the two stocks.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.